Haploidentical stem cell transplantation as a salvage therapy for cord blood engraftment failure in a patient with Fanconi anemia.
A 7-year-old male with Fanconi Anemia who developed primary graft failure following one antigen-mismatched unrelated cord blood transplantation and a nonradiation-based conditioning, underwent a second hematopoietic stem cell transplantation (HSCT) from his 2-loci mismatched haploidentical father, using a nonradiation-based regimen, 79 days after the first HSCT. A sustained hematological engraftment was achieved at 9 days post-second HSCT. At 15 months post-second HSCT; the patient demonstrated normal blood counts, sustained donor chimerism, and no evidence of GVHD. Haploidentical HSCTs as primary or secondary sources of stem cells, with appropriate T-cell depletion, may be a readily available option in the absence of HLA-matched related or unrelated donors.
Rihani
Rawad
R
Bone Marrow and Hematopoietic Stem Cell Transplantation Program, King Hussein Cancer Center, Amman, Jordan. rrihani@khcc.jo
Lataifeh
Isam
I
Halalsheh
Hadeel
H
Hussein
Ayad Ahmed
AA
Al-Zaben
Abdulhadi
A
Abdel-Rahman
Fawzi
F
Sarhan
Mahmoud
M
D002648:Child; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects; D005199:Fanconi Anemia / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006648:Histocompatibility; D006801:Humans; D008297:Male; D016879:Salvage Therapy